Ionis Pharmaceuticals Inc. [NASDAQ: IONS] traded at a high on 10/15/20, posting a 1.22 gain after which it closed the day’ session at $48.29. The company report on October 15, 2020 that Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil.
– Study will evaluate the effectiveness of IONIS-PKK-LRx in reducing the severity of respiratory complications in COVID-19 patients.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that IONIS-PKK-LRx is being evaluated in an investigator-initiated Phase 2 clinical study to determine its effectiveness in reducing the severity of respiratory complications in patients with COVID-19. The trial coordinators are Fernando G. Zampieri, M.D., Ph.D., and Alexandre Biasi Cavalcanti, M.D., Hospital do Coracao (HCor Research Institute), Sao Paulo, Brazil. The study will enroll up to 110 patients at 25 hospitals in Brazil. Ionis has provided IONIS-PKK-LRx and funding to the Brazilian Research for Intensive Care Network (BRICNet) to support the study.
The results of the trading session contributed to over 2838700 shares changing hands. Over the past one week, the price volatility of Ionis Pharmaceuticals Inc. stands at 3.12% while the volatility over the past one month is 3.42%.
The market cap for IONS stock reached $5.01 billion, with 139.35 million shares outstanding and 56.58 million shares in the current float. Compared to the average trading volume of 851.50K shares, IONS reached a trading volume of 2838700 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ionis Pharmaceuticals Inc. [IONS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IONS shares is $67.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IONS stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Ionis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 14, 2020. The new note on the price target was released on September 02, 2020, representing the official price target for Ionis Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Ionis Pharmaceuticals Inc. is set at 1.71, with the Price to Sales ratio for IONS stock in the period of the last 12 months amounting to 5.32. The Price to Book ratio for the last quarter was 4.89, with the Price to Cash per share for the same quarter was set at 22.66. Price to Free Cash Flow for IONS in the course of the last twelve months was 29.17 with Quick ratio for the last quarter at 10.80.
How has IONS stock performed recently?
Ionis Pharmaceuticals Inc. [IONS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.05. With this latest performance, IONS shares dropped by -6.72% in over the last four-week period, additionally sinking by -12.31% over the last 6 months – not to mention a drop of -16.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IONS stock in for the last two-week period is set at 47.65, with the RSI for the last a single of trading hit 52.00, and the three-weeks RSI is set at 44.60 for Ionis Pharmaceuticals Inc. [IONS]. The present Moving Average for the last 50 days of trading for this stock 51.22, while it was recorded at 47.28 for the last single week of trading, and 55.16 for the last 200 days.
Ionis Pharmaceuticals Inc. [IONS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ionis Pharmaceuticals Inc. [IONS] shares currently have an operating margin of +32.59 and a Gross Margin at +98.18. Ionis Pharmaceuticals Inc.’s Net Margin is presently recorded at +26.42.
Return on Total Capital for IONS is now 16.99, given the latest momentum, and Return on Invested Capital for the company is 15.06. Return on Equity for this stock inclined to 23.54, with Return on Assets sitting at 10.05. When it comes to the capital structure of this company, Ionis Pharmaceuticals Inc. [IONS] has a Total Debt to Total Equity ratio set at 53.53. Additionally, IONS Total Debt to Total Capital is recorded at 34.87, with Total Debt to Total Assets ending up at 24.36. Long-Term Debt to Equity for the company is recorded at 53.40, with the Long-Term Debt to Total Capital now at 34.78.
Reflecting on the efficiency of the workforce at the company, Ionis Pharmaceuticals Inc. [IONS] managed to generate an average of $362,990 per employee. Receivables Turnover for the company is 29.62 with a Total Asset Turnover recorded at a value of 0.38.Ionis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.80 and a Current Ratio set at 10.90.
Earnings analysis for Ionis Pharmaceuticals Inc. [IONS]
With the latest financial reports released by the company, Ionis Pharmaceuticals Inc. posted 0.18/share EPS, while the average EPS was predicted by analysts to be reported at -0.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 156.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IONS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ionis Pharmaceuticals Inc. go to 49.00%.
Insider trade positions for Ionis Pharmaceuticals Inc. [IONS]
There are presently around $5,819 million, or 87.93% of IONS stock, in the hands of institutional investors. The top three institutional holders of IONS stocks are: FMR LLC with ownership of 20,810,554, which is approximately -0.714% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 12,306,251 shares of the stock with an approximate value of $594.27 million in IONS stocks shares; and BLACKROCK INC., currently with $417.74 million in IONS stock with ownership of nearly 5.911% of the company’s market capitalization.
Positions in Ionis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 174 institutional holders increased their position in Ionis Pharmaceuticals Inc. [NASDAQ:IONS] by around 9,138,638 shares. Additionally, 159 investors decreased positions by around 7,133,699 shares, while 68 investors held positions by with 104,219,075 shares. The mentioned changes placed institutional holdings at 120,491,412 shares, according to the latest SEC report filing. IONS stock had 50 new institutional investments in for a total of 545,682 shares, while 30 institutional investors sold positions of 652,962 shares during the same period.